Lessons from the TOPCAT trial

New England Journal of Medicine

Volumn 370, Issue 15, 2014, Pages 1453-1454

  McMurray, John J V ^a   O'Connor, Christopher ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IRBESARTAN; NATRIURETIC FACTOR; PLACEBO; SPIRONOLACTONE;

CLINICAL FEATURE; CLINICAL RESEARCH; DRUG EFFICACY; EDITORIAL; ETHNIC DIFFERENCE; GEOGRAPHIC DISTRIBUTION; HEART EJECTION FRACTION; HEART FAILURE; HEART FUNCTION; HOSPITALIZATION; HUMAN; HYPERTENSION; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

FEMALE; HEART FAILURE; HUMANS; MALE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; SPIRONOLACTONE;

EID: 84898730424     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1401231     Document Type: Editorial

References (9)

1. Campbell RT, Jhund PS, Castagno D, Hawkins NM, Petrie MC, McMurray JJ. What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE? J Am Coll Cardiol 2012; 60:2349-56.
2. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology: developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14:803-69. [Erratum, Eur J Heart Fail 2013;15:361-2.]
3. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62(16):e147-e239.
4. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17. (Pubitemid 29407370)
5. Zannad F, McMurray JJV, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11-21.
6. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014;370: 1383-92.
7. Mentz RJ, Kaski JC, Dan GA, et al. Implications of geographical variation on clinical outcomes of cardiovascular trials. Am Heart J 2012;164:303-12.
8. O'Connor CM, Fiuzat M, Swedberg K, et al. Influence of global region on outcomes in heart failure β-blocker trials. J Am Coll Cardiol 2011;58:915-22.
9. Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008;359:2456-67.